Erratum to: Safety and tolerability of Bifidobacterium longum subspecies infantis EVC001 supplementation in healthy term breastfed infants: a phase I clinical trial

Smilowitz, Jennifer T.; Moya, Jackelyn; Breck, Melissa A.; Cook, Chelsea; Fineberg, Annette; Angkustsiri, Kathleen; Underwood, Mark A.

doi:10.1186/s12887-017-0932-7

Cited by 4 publications

(3 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The frequency of defecation was significantly decreased in the M-63 group compared to the placebo group, especially the decrease in watery stools, which was remarkable. A clinical trial using B. infantis EVC001 in neonates showed a similar effect [ 48 ]. The authors speculate that B. infantis consumption promoted the maturation of the intestinal mucosa, based on the fact that Bifidobacterium enhances the barrier function of the intestinal tract [ 6 ] and that B. infantis increases the expression of mRNA for tight junction proteins in intestinal epithelial cells [ 49 ].…”

Section: Discussionmentioning

confidence: 94%

Early Probiotic Supplementation of Healthy Term Infants with Bifidobacterium longum subsp. infantis M-63 Is Safe and Leads to the Development of Bifidobacterium-Predominant Gut Microbiota: A Double-Blind, Placebo-Controlled Trial

Hiraku¹,

Nakata

Murata³

et al. 2023

Nutrients

View full text Add to dashboard Cite

Bifidobacteria are important intestinal bacteria that provide a variety of health benefits in infants. We investigated the efficacy and safety of Bifidobacterium longum subsp. infantis (B. infantis) M-63 in healthy infants in a double-blind, randomized, placebo-controlled trial. Healthy term infants were given B. infantis M-63 (n = 56; 1 × 109 CFU/day) or placebo (n = 54) from postnatal age ≤ 7 days to 3 months. Fecal samples were collected, and fecal microbiota, stool pH, short-chain fatty acids, and immune substances were analyzed. Supplementation with B. infantis M-63 significantly increased the relative abundance of Bifidobacterium compared with the placebo group, with a positive correlation with the frequency of breastfeeding. Supplementation with B. infantis M-63 led to decreased stool pH and increased levels of acetic acid and IgA in the stool at 1 month of age compared with the placebo group. There was a decreased frequency of defecation and watery stools in the probiotic group. No adverse events related to test foods were observed. These results indicate that early supplementation with B. infantis M-63 is well tolerated and contributes to the development of Bifidobacterium-predominant gut microbiota during a critical developmental phase in term infants.

show abstract

Section: Discussionmentioning

confidence: 94%

Early Probiotic Supplementation of Healthy Term Infants with Bifidobacterium longum subsp. infantis M-63 Is Safe and Leads to the Development of Bifidobacterium-Predominant Gut Microbiota: A Double-Blind, Placebo-Controlled Trial

Hiraku¹,

Nakata

Murata³

et al. 2023

Nutrients

View full text Add to dashboard Cite

show abstract

“…It also exerts its anti-inflammatory activity using a toll like receptor (TLR-4) as a mediator to inhibit IL-1β-induced IL-6 secretion and downregulates IL-1 receptor-associated kinase 2 (IRAK-2) mRNA expression in H4 cells [ 100 ], a common adapter protein associated with susceptibility to early-onset asthma [ 101 ]. Supplementation with B. subspecies infantis strain EVC001 is considered safe and tolerable by exclusively breastfed infants [ 102 ], and results in decreased production of IL-1β over the 60 days postnatal [ 103 ]. B. infantis strain R0033 supplementation exerts anti-inflammatory effects as indicated by an increase in the IL-10/IL-12 ratio, while the increase of the TNF-α/IL-10 ratio demonstrates a pro-inflammatory effect in infants following ingestion of Lactobacillus helveticus ( L. helveticus ) strain R0052 [ 104 ].…”

Section: Short-chain Fatty Acids: a Link Between Maternal Vlckd Tmentioning

confidence: 99%

The Role of Short-Chain Fatty Acids in the Interplay between a Very Low-Calorie Ketogenic Diet and the Infant Gut Microbiota and Its Therapeutic Implications for Reducing Asthma

Alsharairi

2020

IJMS

View full text Add to dashboard Cite

Gut microbiota is well known as playing a critical role in inflammation and asthma development. The very low-calorie ketogenic diet (VLCKD) is suggested to affect gut microbiota; however, the effects of VLCKD during pregnancy and lactation on the infant gut microbiota are unclear. The VLCKD appears to be more effective than caloric/energy restriction diets for the treatment of several diseases, such as obesity and diabetes. However, whether adherence to VLCKD affects the infant gut microbiota and the protective effects thereof on asthma remains uncertain. The exact mechanisms underlying this process, and in particular the potential role of short chain fatty acids (SCFAs), are still to be unravelled. Thus, the aim of this review is to identify the potential role of SCFAs that underlie the effects of VLCKD during pregnancy and lactation on the infant gut microbiota, and explore whether it incurs significant implications for reducing asthma.

show abstract

“…Clinical trials assessing safety (as primary or secondary outcomes) of different B. longum subsp. infantis strains, namely EVC001 [19] and M-63 [20] are available. However, to date, B. longum subsp.…”

Section: Introductionmentioning

confidence: 99%

Phylogenetic, Functional and Safety Features of 1950s B. infantis Strains

et al. 2022

View full text Add to dashboard Cite

Strains of Bifidobacterium longum subsp. infantis (B. infantis) are amongst the first to colonize the infant gut, partly due to their capacity to metabolize complex human milk oligosaccharides (HMO), and are proposed to play a key role in the development of the infant gut. Since early life, B. infantis supplementation is of high interest, and detailed phylogenetic, functional and safety characterization of the selected strains should be pursued. Using a combination of long and short-read sequencing technologies, we first decipher the genetic distance between different isolates of the same B. infantis strain. Using the same approach, we show that several publicly available genomes recapitulate this strain-level distance as compared to two of the first strains obtained in the 1950s. Furthermore, we demonstrate that the two 1950s B. infantis strains display different functional and safety attributes, as ATCC 15697 is resistant to streptomycin and shows a preference towards lacto-N-tetraose LNT and sialylated HMOs, while LMG 11588 is sensitive to all tested antibiotics and shows a preference towards fucosylated HMOs. Overall, our work highlights that the current diversity observed in B. infantis is likely underestimated and that strain selection within this subspecies must be the subject of scientific pursuit and associated evaluation.

show abstract

Erratum to: Safety and tolerability of Bifidobacterium longum subspecies infantis EVC001 supplementation in healthy term breastfed infants: a phase I clinical trial

Cited by 4 publications

References 1 publication

Early Probiotic Supplementation of Healthy Term Infants with Bifidobacterium longum subsp. infantis M-63 Is Safe and Leads to the Development of Bifidobacterium-Predominant Gut Microbiota: A Double-Blind, Placebo-Controlled Trial

Early Probiotic Supplementation of Healthy Term Infants with Bifidobacterium longum subsp. infantis M-63 Is Safe and Leads to the Development of Bifidobacterium-Predominant Gut Microbiota: A Double-Blind, Placebo-Controlled Trial

The Role of Short-Chain Fatty Acids in the Interplay between a Very Low-Calorie Ketogenic Diet and the Infant Gut Microbiota and Its Therapeutic Implications for Reducing Asthma

Phylogenetic, Functional and Safety Features of 1950s B. infantis Strains

Contact Info

Product

Resources

About